Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 5008Neoplasms 4199Prostatic Neoplasms 2428Carcinoma, Non-Small-Cell Lung 2265Colorectal Neoplasms 2053Lung Neoplasms 1706Multiple Myeloma 1459Lymphoma 1405Leukemia, Myeloid, Acute 1382Neoplasm Metastasis 1376Melanoma 1270Pancreatic Neoplasms 1200Leukemia 1196Ovarian Neoplasms 1193Lymphoma, Non-Hodgkin 1132Precursor Cell Lymphoblastic Leukemia-Lymphoma 1091Head and Neck Neoplasms 1056Leukemia, Lymphocytic, Chronic, B-Cell 994Lymphoma, Follicular 897Colonic Neoplasms 896Brain Neoplasms 877Stomach Neoplasms 858Recurrence 855Carcinoma, Hepatocellular 846Glioblastoma 842Lymphoma, Large B-Cell, Diffuse 772Rectal Neoplasms 759Uterine Cervical Neoplasms 729Carcinoma, Renal Cell 705Hodgkin Disease 698

Interventions

encorafenib 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Interventional × Advanced BRAF Mutant Cancers × Clear all
NCT03843775 2024-10-21

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
17 enrolled 9 charts

Advanced BRAF Mutant Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡